Skip to content

Nephrologic Prognosis 10 Years After Diabetes Cell Therapy

Nephrologic Prognosis 10 Years After Diabetes Cell Therapy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02627690
Acronym
PRONOCELDIAB
Enrollment
45
Registered
2015-12-11
Start date
2014-11-03
Completion date
2021-11-29
Last updated
2022-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Islet Transplantation

Brief summary

Islet transplantation for type 1 diabetes results are still improving, and actually Insulin-independence with normal HbA1c is obtained in 50% of patients after 5 years, 80% of c-peptide positive patients. In addition to the need of 2 or 3 surgical or radiological interventions to inject islets, an immunosuppressive regimen is needed, which can be deleterious, particularly on kidneys. Moreover, long term beneficial effects of islet transplantation on stabilization or prevention of macro and micro vascular complications of diabetes has not been evaluated. In a preliminary work, it was observed a stabilisation or improvement of microvascular complications when compared to pre-transplant data. The aim of this study is to compare the evolution of diabetes complications, especially nephrologic, 10 years after islet transplantation and to compare it to patients with a brittle diabetes, 10 years after evaluation for islet transplantation, finally not performed. This case-control study will evaluate nephrologic parameters (creatinine, MDRD creatinine clearance, microalbuminuria, proteinuria) and other micro and macro-vascular complications of type 1 diabetes) before islet transplantation and 10 years after the transplantation or after the first evaluation in patients who finally did not underwent islet transplantation for various non nephrologic reasons

Interventions

OTHERislet transplanted

islet transplantation

OTHERnon islet transplanted

no islet transplantation (for a non nephrologic reason)

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 77 Years
Healthy volunteers
No

Inclusion criteria

* Type 1 diabetic patients, with or without previous renal transplantation who benefit at least 5 years before the inclusion of clinical evaluation in order to perform an islet transplantation * Who either benefit of islet transplantation or did not and treated with optimized insulin therapy

Exclusion criteria

* C-peptide positive diabetes * Type 1 diabetic patient non-grafted of islets due to albuminuria\> 300mg / 24h or MDRD \<50 ml / min during the pre-transplant evaluation (exclusion criterion for islet transplantation) * Patients that can not receive clear information * Refusal to sign the consent * Psychiatric Pathology * Participation in another study excluding the possibility of participating in another protocol. * Pregnant or breast feeding women * Patients under guardianship, persons deprived of freedom * Lack of coverage by the social security system

Design outcomes

Primary

MeasureTime frameDescription
Modification of Diet in Renal Disease (MDRD)At 10 yearsmeasure the difference of Modification of Diet in Renal Disease (MDRD) between the two groups according to the presence or absence of an islet transplant.

Secondary

MeasureTime frame
number of cardiovascular eventsAt 10 years
number of deathsAt 10 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026